Effusion Cytology
Defining and targeting tumor-associated macrophages in malignant mesothelioma
Proceedings of the National Academy of Sciences of the United States of America 2023 February 28 [Link] Licun Wu, Mikihiro Kohno, Junichi Murakami, Amin Zia, Jonathan Allen, Hana Yun, Meilin Chan, Cristina Baciu, Mingyao Liu, Veronique Serre-Beinier, Michele De Palma, Emanuela Felley-Bosco, Jonathan Yeung, Trevor J Pugh, Marc de Perrot Abstract Defining the ontogeny of…
Read MoreIdentification of Highly Sensitive Pleural Effusion Protein Biomarkers for Malignant Pleural Mesothelioma by Affinity-Based Quantitative Proteomics
Cancers 2023 January 19 [Link] Nicolai B Palstrøm, Martin Overgaard, Peter Licht, Hans C Beck Abstract Malignant pleural mesothelioma (MPM) is an asbestos-associated, highly aggressive cancer characterized by late-stage diagnosis and poor prognosis. Gold standards for diagnosis are pleural biopsy and cytology of pleural effusion (PE), both of which are limited by low sensitivity and…
Read MoreThe cytologic diagnosis of mesothelioma: are we there yet?
Journal of the American Society of Cytopathology 2022 December 26 [Link] Claire W Michael Abstract Introduction: Mesothelioma is a rare but highly aggressive malignancy with poor prognosis that frequently present with recurrent effusions. Establishing the diagnosis by cytology can lead to early diagnosis and treatment and consequently improve prognosis. Materials and methods: This review examines…
Read MoreProtocol for a prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma (ASSESS-meso)
BMJ Open 2022 November 10 [Link] Ruairi J H Conway, Jenny Symonds, Deborah Walton, Janet Probets, Charles Comins, Louise Stadon, John E Harvey, Kevin G Blyth, Nick A Maskell, Anna C Bibby Abstract Introduction: Mesothelioma is a heterogeneous disease that can be challenging to monitor and prognosticate. ASSESS-meso is a multicentre, prospective, longitudinal observational cohort…
Read MoreMalignant Peritoneal Mesothelioma Features Shown by FDG-PET/CT
Cancer Diagnosis & Prognosis 2022 November 3 [Link] Kozo Kuribayashi, Kazuhiro Kitajima, Toshiyuki Minami, Masataka Ikeda, Koichiro Yamakado, Takashi Kijima Abstract Background/aim: Malignant peritoneal meso-thelioma (MPeM) has no specific imaging findings that can distinguish it from other peritoneal tumors and the accuracy of peritoneal cytology is low, therefore definitive diagnosis is usually performed by histology.…
Read MoreCytological Diagnosis of Malignant Mesothelioma: A Case Series
Journal of Cytology 2022 July-September [Link] Sakshi Dahiya, Meeta Singh, Shyama Jain, Bembem Khuraijam, Naman Suroya, Shramana Mandal Abstract Background: Mesotheliomas are neoplasms of the serosal lining of the body cavities. Diagnosis requires a multimodal approach of clinical findings, cytology, and histopathology with immunohistochemistry (IHC). The published sensitivity of cytology for diagnosing mesothelioma ranges from…
Read MoreUtility of BerEp4/calretinin and desmin/epithelial membrane antigen (EMA) dual immunocytochemical staining in effusion cytology
Cancer Medicine 2022 October 19 [Link] Anders Hjerpe, Enes Demir, Sulaf Abd-Own, Katalin Dobra Abstract Background: Pleural mesothelioma (PM) is typically diagnosed late during the disease. Earlier detection can increase the chance of effective therapy. Recurrent pleural effusions are the earliest symptoms displaying an array of cytomorphological changes from reactive atypia to malignancy. Diagnosis is…
Read MoreLong-term Outcomes and Risk Factors of Residual Thoracic Spaces after Pleurectomy/Decortication for Mesothelioma
European Journal of Cardiothoracic Surgery 2022 October 19 [Link] Akifumi Nakamura, Masaki Hashimoto, Nobuyuki Kondo, Seiji Matsumoto, Toru Nakamichi, Kozo Kuribayashi, Takashi Kijima, Hiroshi Kodama, Koichiro Yamakado, Seiki Hasegawa Abstract Objectives: The residual thoracic spaces (RTS) after pleurectomy/decortication (P/D) remain unexplored to date. Hence, this study aims to examine the details and risk factors of…
Read MoreDiagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma
Journal of the American Society of Cytopathology 2022 July 9 [Link] Louise Andersen Lynggård, Vasiliki Panou, Weronika Szejniuk, Oluf Dimitri Røe, Christos Meristoudis Abstract Introduction: Serous effusion is often the first sign of mesothelioma. Diagnosis based on cytologic material from the effusions remains controversial and complementary biopsy is usually required. However, obtaining representative tissue sample…
Read MoreClinical significance of 9P21 gene combined with BAP1 and MTAP protein expression in diagnosis and prognosis of mesothelioma serous effusion
Biomedical Reports 2022 June 7 [Link] Guan-Ying Ma, Shuai Shi, Ping Wang, Xing-Guang Wang, Zhi-Gang Zhang Abstract The diagnostic value of the 9P21 gene determined using fluorescence in situ hybridization (FISH) combined with BRCA1-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP) expression detection by immunohistochemistry, was investigated in serous effusion samples of malignant mesothelioma. A…
Read More